Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Aurinia Pharmaceuticals Inc - Common Shares
(NQ:
AUPH
)
17.28
+0.03 (+0.16%)
Delayed Quote
Updated: 11:04 AM EDT, Oct 28, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aurinia Pharmaceuticals Inc - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
June 30, 2023
Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top...
Via
Benzinga
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday
↗
June 30, 2023
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Aurinia Surges As It Explores 'Strategic Alternatives,' Including A Potential Buyout
↗
June 30, 2023
The company makes a lupus nephritis treatment that could easily bolt onto a suitor, analysts say.
Via
Investor's Business Daily
Aurinia Pharmaceuticals Earnings Perspective: Return On Capital Employed
↗
May 18, 2023
Via
Benzinga
Aurinia Pharmaceuticals: Q1 Earnings Insights
↗
May 04, 2023
Via
Benzinga
Why Aurinia Pharmaceuticals Stock Is Glowing Green Today
↗
April 11, 2023
Investors appear to be cheering another patent win by the company.
Via
The Motley Fool
Why Are Aurinia Pharmaceuticals Shares Trading Higher Today
↗
June 30, 2023
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) initiated an exploration of strategic alternatives, including a potential sale, merger, or
Via
Benzinga
Why Renalytix Are Trading Higher By Over 48%; Here Are 20 Stocks Moving Premarket
↗
June 30, 2023
Gainers Renalytix Plc (NASDAQ: RNLX) shares surged 48.7% to $3.02 in pre-market trading after the company received FDA De Novo marketing authorization for its KidneyIntelX.dkd prognostic test.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
↗
June 30, 2023
It's the final day of trading this week and we're starting off with a breakdown of the biggest pre-market stock movers worth watching today!
Via
InvestorPlace
Tesla, Nike, Sigilon Therapeutics Among Top Trending Stocks Today
↗
June 29, 2023
Via
Benzinga
Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
June 29, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy
June 20, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone
June 01, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees
May 26, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Announces 2023 Annual General Meeting Results
May 17, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference
May 09, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results
May 04, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis
May 03, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tesla, AMD, Ford, Starbucks, Aurinia Pharma: Why These 5 Stocks Are Drawing Investors' Attention Today
↗
May 02, 2023
Via
Benzinga
ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual General Meeting
May 02, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)
May 02, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Glass Lewis Recommends Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual Meeting
April 28, 2023
From
Aurinia
Via
Business Wire
3 Biotechs That Might Get Bought Out in 2023
↗
April 26, 2023
Biotech is expected to be a hotbed of mergers and acquisitions this year.
Via
The Motley Fool
Toni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys
April 25, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Second Quarter Outlook For Biotech Stocks
↗
April 25, 2023
Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity.
Via
Talk Markets
Is Aurinia Pharmaceuticals Up for Grabs? Shareholder Suggests a Quick Sale for a Bigger Payday
↗
April 24, 2023
Via
Benzinga
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023
April 24, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office
April 11, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
3 Stocks That Already Doubled in 2023 and Could Keep Climbing
↗
April 11, 2023
The gains these stocks notched in the first few months of the year could be the beginning of a much longer bull run.
Via
The Motley Fool
What's Going On With Aurinia Pharmaceuticals Stock Wednesday?
↗
April 05, 2023
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading higher Wednesday after the company announced "promising results" from its AURORA
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
